Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)

T. Kim; J. Taieb; M. Passhak; T. Kim; S. Kim; R. Geva; E. Hofsli; G. Perl; S. Yalcin; A. Hubert; B. Somer; Z. Wong; A. Wang; P. Leconte; D. Fogelman; V. Heinemann

doi:10.1016/j.annonc.2022.04.171

Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)

T. Kim
, J. Taieb
, M. Passhak
, T. Kim
, S. Kim
, R. Geva
, E. Hofsli
, G. Perl
, S. Yalcin
, A. Hubert
, B. Somer
, Z. Wong
, A. Wang
, P. Leconte
, D. Fogelman
, V. Heinemann

University of Ulsan
Assistance Publique Hopitaux Paris (APHP)
Rambam Health Care Campus
Seoul National University (SNU)
Sungkyunkwan University (SKKU)
Tel Aviv University
Norwegian University of Science and Technology (NTNU)
University of Tennessee System
Monash University
Merck & Company
Dept Hematol Oncol & Pulmonol

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S277-S277
Number of pages	1
Journal	Annals of Oncology
Volume	33
DOIs	https://doi.org/10.1016/j.annonc.2022.04.171
Publication status	Published - Jun 2022
Event	ESMO 24th World Congress on Gastrointestinal Cancer - Barcelona, Spain Duration: 29 Jun 2022 → 2 Jul 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.annonc.2022.04.171

Cite this

Kim, T., Taieb, J., Passhak, M., Kim, T., Kim, S., Geva, R., Hofsli, E., Perl, G., Yalcin, S., Hubert, A., Somer, B., Wong, Z., Wang, A., Leconte, P., Fogelman, D., & Heinemann, V. (2022). Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC). Annals of Oncology, 33, S277-S277. https://doi.org/10.1016/j.annonc.2022.04.171

@article{dedcf13e3f15477da6fda4316cceb73f,

title = "Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)",

author = "T. Kim and J. Taieb and M. Passhak and T. Kim and S. Kim and R. Geva and E. Hofsli and G. Perl and S. Yalcin and A. Hubert and B. Somer and Z. Wong and A. Wang and P. Leconte and D. Fogelman and V. Heinemann",

year = "2022",

month = jun,

doi = "10.1016/j.annonc.2022.04.171",

language = "English",

volume = "33",

pages = "S277--S277",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

note = "ESMO 24th World Congress on Gastrointestinal Cancer ; Conference date: 29-06-2022 Through 02-07-2022",

}

Kim, T, Taieb, J, Passhak, M, Kim, T, Kim, S, Geva, R, Hofsli, E, Perl, G, Yalcin, S, Hubert, A, Somer, B, Wong, Z, Wang, A, Leconte, P, Fogelman, D & Heinemann, V 2022, 'Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)', Annals of Oncology, vol. 33, pp. S277-S277. https://doi.org/10.1016/j.annonc.2022.04.171

TY - JOUR

T1 - Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)

AU - Kim, T.

AU - Taieb, J.

AU - Passhak, M.

AU - Kim, T.

AU - Kim, S.

AU - Geva, R.

AU - Hofsli, E.

AU - Perl, G.

AU - Yalcin, S.

AU - Hubert, A.

AU - Somer, B.

AU - Wong, Z.

AU - Wang, A.

AU - Leconte, P.

AU - Fogelman, D.

AU - Heinemann, V.

PY - 2022/6

Y1 - 2022/6

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000823826500094&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1016/j.annonc.2022.04.171

DO - 10.1016/j.annonc.2022.04.171

M3 - Meeting Abstract

SN - 0923-7534

VL - 33

SP - S277-S277

JO - Annals of Oncology

JF - Annals of Oncology

T2 - ESMO 24th World Congress on Gastrointestinal Cancer

Y2 - 29 June 2022 through 2 July 2022

ER -

Phase 3 study of MK4280A (coformulated favezelimab and pembrolizumab) versus standard of care in previously treated PD-L1epositive metastatic colorectal cancer (mCRC)

UN SDGs

Access to Document

Other files and links

Cite this